Enasidenib Approved for AML, but Best Uses Unclear [News in Brief]

The FDA approved the targeted therapy enasidenib for patients with refractory or relapsed acute myeloid leukemia with mutant IDH2. The drug produces remissions in some patients and may reduce the need for blood transfusions, although researchers acknowledge that the FDA's approval came with less supporting evidence than usual.

http://ift.tt/2wuhJog